Positron emission tomography (PET) provides a powerful means to non-invasively image and quantify protein expression and biochemical changes in living subjects at nano- and picomolar levels. As the field of molecular imaging develops, and as advances in the biochemistry, pharmacology, therapeutics, and molecular biology of disease are made, there is a corresponding increase in the number of clinically relevant, novel disease-associated biomarkers that are brought to the attention of those developing imaging probes for PET. In addition, due to the high specificity of the PET radiotracers being developed, there is a demand for PET cameras with higher sensitivity and resolution. This manuscript reviews advances over the past five years in clinical and pre-clinical PET instrumentation and in new PET probes and imaging methods associated with the latest trends in the molecular imaging of cancer. Included in the PET tracer review is a description of new radioligands for steroid receptors, growth factor receptors, receptor tyrosine kinases, sigma receptors, tumor-associated enzymes, gene reporter probes, markers for tumor hypoxia and metabolism, and sites associated with angiogenesis and cellular proliferation. The use of PET imaging in drug development, including the monitoring of cancer chemotherapy, also is discussed.

Assessment of cancer-associated biomarkers by positron emission tomography: Advances and challenges / Collier, T. L.; Lecomte, R.; Mccarthy, T. J.; Meikle, S.; Ruth, T. J.; Scopinaro, Francesco; Signore, Alberto; Waterhouse, R. N.. - In: DISEASE MARKERS. - ISSN 0278-0240. - STAMPA. - 18:(2002), pp. 211-247.

Assessment of cancer-associated biomarkers by positron emission tomography: Advances and challenges

SCOPINARO, Francesco;SIGNORE, Alberto;
2002

Abstract

Positron emission tomography (PET) provides a powerful means to non-invasively image and quantify protein expression and biochemical changes in living subjects at nano- and picomolar levels. As the field of molecular imaging develops, and as advances in the biochemistry, pharmacology, therapeutics, and molecular biology of disease are made, there is a corresponding increase in the number of clinically relevant, novel disease-associated biomarkers that are brought to the attention of those developing imaging probes for PET. In addition, due to the high specificity of the PET radiotracers being developed, there is a demand for PET cameras with higher sensitivity and resolution. This manuscript reviews advances over the past five years in clinical and pre-clinical PET instrumentation and in new PET probes and imaging methods associated with the latest trends in the molecular imaging of cancer. Included in the PET tracer review is a description of new radioligands for steroid receptors, growth factor receptors, receptor tyrosine kinases, sigma receptors, tumor-associated enzymes, gene reporter probes, markers for tumor hypoxia and metabolism, and sites associated with angiogenesis and cellular proliferation. The use of PET imaging in drug development, including the monitoring of cancer chemotherapy, also is discussed.
2002
01 Pubblicazione su rivista::01a Articolo in rivista
Assessment of cancer-associated biomarkers by positron emission tomography: Advances and challenges / Collier, T. L.; Lecomte, R.; Mccarthy, T. J.; Meikle, S.; Ruth, T. J.; Scopinaro, Francesco; Signore, Alberto; Waterhouse, R. N.. - In: DISEASE MARKERS. - ISSN 0278-0240. - STAMPA. - 18:(2002), pp. 211-247.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/501627
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 20
social impact